Cellestia Biotech AG, a clinical-stage biopharma company, has secured CHF 20 million in Series B funding. The investors included FC Capital and Partners Investment.
Source: Press Release
Cellestia Biotech picks up Series B
Cellestia Biotech AG, a clinical-stage biopharma company, has secured CHF 20 million in Series B funding.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: